Compare Alliant Energy Corporation (LNT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Neurocrine Biosciences Inc — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LNT | NBIX | |
|---|---|---|
Market Cap | $16.99B | $14.36B |
Volume | 2,488,387 | 1,237,180 |
Sector | Utilities | Health |
52-Week High | $78.03 | $185.50 |
52-Week Low | $63.21 | $123.10 |
Typical Hold Time | 64 Days | 23 Days |
Enterprise Value | $29.08B | $14.37B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.85, up 0.98% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported 2025 revenue of $4.36B and net income of $810M, with a net margin of 18.56%. A $13.4B capital investment plan supports long-term growth, while analyst consensus is a Buy with a $77.00 price target, implying significant upside from current levels.
Outlook remains positive due to steady utility demand and data center growth, but risks include rising debt levels and cost pressures. The stock offers a defensive profile with a 23-year dividend growth history, though valuation multiples like a P/E of 20.74 require sustained earnings expansion to justify further gains.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
